Sulfonamides are vital components in many pharmaceuticals and agrochemicals, yet traditional synthesis methods face challenges due to instability and harsh reaction conditions. In response, Dr. Ghayoor Abbas Chotana from Department of Chemistry and Chemical Engineering SBASSE along with his team members Ismat Nawaz, Maryam Nawaz, and Dr. Rahman Shah Zaib Saleem, have developed an innovative catalytic approach for Sulfur (VI) Fluoride Exchange (SuFEx) reactions, published in Advanced Synthesis & Catalysis.
Using affordable organic bases and leveraging the unexpected role of glass reaction vessels, the team’s method simplifies sulfonamide synthesis while adhering to green chemistry principles. This breakthrough enables safer, more efficient production of sulfonamides for drug discovery and highlights how everyday materials like glass can influence chemical reactions.
Read Full Paper here. 
The work reflects LUMS’ commitment to advancing science and sustainability, contributing to global innovation in chemistry.
 

 Dr. Basit Yameen, from the Department of Chemistry, has made remarkable contributions to the field of polymer chemistry over the years. In 2014-15, he was recognized as an Emerging Investigator by the Royal Society of Chemistry’s Polymer Chemistry journal. Now, nearly a decade later, he has been honored once again, this time being identified and recommended by the journal’s editorial and advisory boards as one of the Pioneering Investigators who have firmly established themselves as pioneers of the field of polymer chemistry. This prestigious recognition celebrates Dr. Yameen’s lasting and impactful contributions to the advancement of polymer science, further solidifying his position as a leading figure in the field.

Selenium is a vital trace element that plays a crucial role in our health, influencing various biochemical pathways due to its antioxidant properties. In nature, it often finds its way to our plates through foods like tuna, enriching our bodies with its antioxidant prowess.

The intricate relationship between Selenium and antioxidant properties has been extensively studied by researchers in the field, including Dr. Rahman Shah Zaib Saleem from the Department of Chemistry and Chemical Engineering at SBASSE, who is one of the contributors to a paper on Selenium derivatives. The paper was published after Dr. Rahman’s DAAD (Deutscher Akademischer Austauschdienst) scholarship visit to Germany in 2019 in collaboration with eleven international researchers, including Dr Rama Alhasan, Dr. Guilherme M. Martins, Dr. Pedro P. de Castro, Dr. Claus Jacob.  

Selenium, acting as an antioxidant powerhouse, takes center stage in this study. Nature carries very few selenium containing organic compounds, Selenoneine being one of those. In this work, the team has worked on the preparation of novel organoselenium compounds. The research zeroes in on Selenohydantoin derivatives, synthetic compounds inspired by Selenoneine. These derivatives, with their fascinating range of pharmacological applications, hold the potential to serve not just as antioxidants but as versatile agents with capabilities spanning anti-inflammatory, anticancer, and antiplatelet realms. Through Selenocysteine enzymes like Glutathione Peroxidase, it acts as a powerful defender, effectively reducing peroxides to explore their potential in combating oxidative stress, a state where an imbalance occurs between the production of free radicals and the body's ability to neutralize them.

Using a unique synthetic method, the researchers synthesized Selenohydantoin molecules, paving the way for a comprehensive evaluation of their antioxidant capabilities. The study employed classical radical scavenging and metal-reducing techniques to unravel the true potential of these synthetic compounds. Cytocompatibility assays demonstrated that the Selenohydantoin derivatives were not only effective antioxidants but also non-toxic to primary human aortic smooth muscle cells. Cytocompatibility refers to the compatibility of a substance with living cells, ensuring that these compounds do not harm or disrupt normal cell function, a promising aspect for further biological evaluations.

Among the synthesized compounds, those adorned with trifluoro-methyl (-CF3) and chlorine (-Cl) substituents emerged as molecules displaying noteworthy antioxidant activities. Dr. Rahman's work highlights these compounds as potential candidates for future biological studies, offering hope for innovative therapies against chronic diseases. This research focuses not only on synthetic compounds but also on the broader context of organoselenium compounds in living organisms. Looking into the future a larger picture emerges - synthesis of Selenium-based compounds could play a crucial role in developing novel and effective prevention and treatments for diseases such as cancer, cardiovascular diseases, cystic fibrosis and rheumatoid arthritis.

Dr. Rahman has recently been honored with another DAAD (Deutscher Akademischer Austauschdienst) scholarship grant by the German Academic Exchange Service. Through the scholarship Dr. Rahman and his research team will delve into the study of various signaling proteins and kinases, with a particular focus on the innovative molecule known as Proteolysis Targeting Chimeras (PROTACs). To learn more about Dr. Saleem's cutting-edge research and the potential impact of PROTACs on cancer treatment, follow this link.

“We sympathise with all the families who have suffered the loss of a child,” expressed a spokesperson from Sanofi Pasteur, the French multinational pharmaceutical company, upon the deaths of school-age children in the Philippines after being administered Sanofi’s dengue virus vaccine, Dengvaxia. Notably, no deaths had been reported during more than a decade-long clinical trials of the world’s first dengue vaccine. However, in November 2017, Sanofi disclosed that Dengvaxia “might increase the risk of severe disease in people who had never been exposed to the virus. 

Despite extensive efforts, current dengue prevention strategies, including vaccinations, have significant limitations, leaving no specific treatment for dengue fever. This vector-borne disease, primarily affecting Asia, is transmitted by infected mosquitoes (vectors) that carry and transmit the dengue virus from person to person, causing severe fever.

Could undercounted infections explain the lack of attention to dengue’s severity?
A 2013 study published in Nature estimated the true total of infections to be more than three times the estimate of the World Health Organisation. 
The traditional approach of developing new drugs from scratch can be both time-consuming and expensive. Therefore, researchers at SBASSE (Syed Babar Ali School of Science and Engineering) have pursued an alternative strategy known as drug repurposing. This approach involves identifying existing drugs that might be effective against diseases different from their original intended use. In this study, led by Hafiza Nosheen Saleem under the supervision of Dr Muhammad Saeed, a library of 1127 small molecules, initially designed as antivirus drugs, were screened to determine their potential efficacy against the dengue virus.
Nosheen and Dr Saeed, alongside their collaborators Summara Kousar, Ammar Hassan Jiskani, Iqra Sohail and Dr Amir Faisal, focused their efforts on a specific protein within the dengue virus known as DENV NS2B/NS3 protease. This protein plays a crucial role in the virus's life cycle, and inhibiting it could disrupt the virus's ability to replicate. Four molecules in the screen library, ABT263, ABT737, AT101 and TW37, demonstrated promise as inhibitors of the NS2B/NS3 protease. These molecules were initially developed as inhibitors for B-cell lymphoma 2 (Bcl-2), a member of the protein family. Notoriously associated with the survival of certain types of cancer cells, Bcl-2 plays a key role in aiding cancer cells to withstand chemotherapy. For instance, ABT263 is currently being tested for the treatment of high-grade triple-negative breast cancer and ovarian cancer.  

To assess the effectiveness of these molecules in inhibiting the NS2B/NS3 protease, the researchers employed a metric called IC50, representing the "half-maximal inhibitory concentration." This metric gauges how effectively a molecule can inhibit the protease. Further analysis of these molecules' inhibition mechanisms revealed that ABT263 and ABT737 competitively inhibited the protease by binding to the same site as the target substrate. In contrast, AT101 and TW37 were identified as non-competitive inhibitors, binding to a different site and inducing changes in the enzyme's structure or activity.

The study suggests that the identified inhibitors have the potential to be developed into specific anti-dengue therapeutics. This is a promising avenue for further research and development, as these molecules have already undergone testing for their safety and pharmacological properties as anticancer drugs. With the aim of preventing tragic incidents like the loss of school-age children to dengue in the Philippines, this research provides hope for improved treatments and enhanced protection against this mosquito-borne disease.